Novo Nordisk announced on the 17th that Novo Nordisk, the world's first and currently the only glucagon like peptide-1 receptor agonist (GLP-1) weekly formulation for long-term weight management, has been officially launched in China. Novogene (Simeglutide Injection for Long term Weight Management) can achieve an average weight loss of about 17%, and its weight loss effect can last for at least 2 years. As of now, semaglutide has accumulated over 22 million patient years of exposure experience.